NCT02053220已完成1 期
A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Akamis Bio
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Composite measure of viral delivery and spread
研究概览
简要总结
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all the following criteria to be eligible for participation:
- •Able and willing to provide written informed consent and to comply with the study protocol
- •Age ≥ 18 years
- •Patients with histologically confirmed resectable colon cancer, NSCLC (squamous and non-squamous), bladder cancer (urothelial cell carcinoma) or RCC (renal cell carcinoma), scheduled for resection of primary tumour and with planned resection of draining lymph nodes for colon cancer
- •Diagnostic colonoscopy performed at the study centre (Cohorts A and B only) or a referral centre (Cohort B only) and a report from this colonoscopy available for the study
- •Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy for cohorts A and B or by CT-scan for cohorts C, D and E.
- •At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time of first administration of ColoAd1
- •Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies.
- •Able to undergo surgery with general anaesthesia
- •Surgery planned and administration of ColoAd1 feasible within
- •15 days of planned surgery (following IT administration or following first dose of IV administration) for cohorts A and B
- •10 - 25 days of first ColoAd1 administration for cohorts C, D and E
- •ECOG Performance Status Score of 0 or 1
- •Adequate renal function
- •Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥60 mL/min,
- •Absence of clinically significant haematuria on urinalysis: dipstick < 2+
- •Absence of clinically significant proteinuria on urinalysis: dipstick < 2+.
- •Adequate hepatic function
- •serum bilirubin <1.5 x ULN
- •AST and ALT ≤ 3 x ULN
- •Adequate bone marrow function:
- •ANC ≥ 1.5 x 109/L,
- •platelets ≥ 100 x 109/L,
- •haemoglobin ≥ 90 g/L
- •Adequate coagulation tests: INR ≤ 1.5 x ULN;
- •For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative pregnancy test must be documented prior to enrolment;
- •For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period and for at least 3 months after the last dose of study drug;
- •For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug
排除标准
- •for all patients:
- •Patients who meet any of the following criteria are not eligible for enrolment:
- •Rectal tumours; (cohorts A and B);
- •An obstructive tumour of the intestine (cohorts A and B only) or of the urinary tract (cohort D);
- •Any condition necessitating surgery in less than 8 days (cohorts A or B) or 10 days (cohorts C, D or E);
- •Pregnant or lactating (nursing) women;
- •Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks);
- •Splenectomy
- •Prior allogeneic or autologous bone marrow or organ transplantation
- •Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
- •Active viral disease, positive serology for HIV, hepatitis B or hepatitis C
- •Use of the following anti-viral agents:
- •ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1;
- •or PEG-IFN (within 14 days prior to day 1);
- •Administration of an investigational drug within 28 days prior to first dose of ColoAd1
- •Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1
- •Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ)
- •Known CNS metastasis
- •Inflammatory diseases of the bowel (cohorts A and B only) or any inflammatory disease that may require treatment with corticosteroids.
- •Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
- •Known allergy to treatment medication or its excipients
- •Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
研究组 & 干预措施
Intra-tumoural cohort
Experimental
干预措施: Colo-Ad1 (Biological)
Intra-venous cohort
Experimental
干预措施: Colo-Ad1 (Biological)
结局指标
主要结局
Composite measure of viral delivery and spread
时间窗: Up to Day 25
To assess the pattern of viral delivery and viral spread of ColoAd1 within tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung CancerStage IVB Lung Cancer AJCC v8Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8NCT03546361Jonsson Comprehensive Cancer Center24
招募中
1 期
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma, Head And NeckSquamous Cell Head and Neck CarcinomaOral CavityOral Cavity CarcinomaHead and Neck Cancers- Squamous CellSolid TumorsHNSCCSCC - Squamous Cell CarcinomaSCCHNHead Neck CancerHead and Neck Squamous Cell CancerSquamous Cell Carcinoma of the Head and NeckNCT06736379VLP Therapeutics41
已完成
1 期
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast CancerEstrogen Receptor NegativeProgesterone Receptor NegativeRecurrent Head and Neck CarcinomaStage IV Breast CancerHER2/Neu NegativeHER2/Neu PositiveInvasive Breast CarcinomaProgesterone Receptor PositiveEstrogen Receptor PositiveHead and Neck Squamous Cell CarcinomaTriple-Negative Breast CarcinomaNCT01846091Mayo Clinic12
撤回
1 期
Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to LiverColorectal NeoplasmsNCT00035919University of Southern California
已完成
1 期
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00023933National Cancer Institute (NCI)15